相关实验视频

Updated: May 9, 2025

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

洞察到非常老年多发性骨髓瘤治疗从堪萨伊骨髓瘤论坛的洞察力

Yusuke Okayama^1,2, Teruhito Takakuwa^1,3, Yuji Shimura⁴

¹Department of Hematology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.

Hematology (Amsterdam, Netherlands)

|April 29, 2025

概括

针对老年患者多发性骨髓瘤 (MM) 的新药有希望,但不良事件 (AE) 威胁着治疗的继续. 谨慎管理至关重要,在这个人群中延长时间到下一次治疗 (TTNT).

科学领域:

血液学血液学血液学
老年医学老年医学
在瘤学瘤学.

背景情况:

全球人口老龄化需要对老年人多发性骨髓瘤 (MM) 进行有效的治疗.
80岁及以上的MM患者治疗的现实数据仍然有限.
这项研究解决了对非常老年MM患者基于证据的治疗策略的需求.

研究的目的:

评估80岁及以上患者多发性骨髓瘤 (MM) 新型治疗剂的疗效和安全性.
分析基于不同时间段的治疗结果,反映出新药的引入.
为了确定影响治疗延续和生存的因素,在这个特定的患者队列.

主要方法:

在1997年至2020年期间诊断出MM的519名患者的回顾性分析.
根据治疗年份,患者被分为三组:至2010年,2011-2015年和2016-2020年.
评估的关键结果包括到下一次治疗的时间 (TTNT),无进展生存期 (PFS),整体生存期 (OS) 和不良事件发生率 (AE).

主要成果:

患者的中位数年龄为83岁,中位数为2个治疗线.
在最近的治疗组 (2016-2020年) 中,时间到下一次治疗 (TTNT) 显著缩短.
虽然PFS和OS的中位数没有显著差异,但近年来AEs和因AEs而中止治疗的发生率有所增加,停药时间缩短.

结论:

不良事件 (AE) 对接受新药的多发性骨髓瘤 (MM) 非常老年患者的持续治疗构成重大挑战.
需要有效的管理策略来缓解AE并延长到下一次治疗 (TTNT) 的时间.
进一步研究优化老年MM患者的支持性护理和治疗方案是有必要的.

关键词:

多发性骨髓瘤是一种多发性骨髓瘤.不良事件不良事件不良事件新诊断的新诊断的人.时间到下一次治疗.非常老的非常老的人.

更多相关视频

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...